Compare Stocks: IMA, ABOS, KROS, and PEPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$3.18 +2.9%	$2.59	$1.21 ▼ $3.60	$223.46M	0.37	364,901 shs	315,369 shs
IMA ImageneBio	$4.85 -0.8%	$5.66	$3.94 ▼ $9.47	$55.45M	0.7	11,092 shs	15,462 shs
KROS Keros Therapeutics	$11.32 +1.9%	$10.81	$9.69 ▼ $22.55	$220.28M	1.01	192,149 shs	65,635 shs
PEPG PepGen	$3.11 -2.2%	$2.46	$1.30 ▼ $7.80	$220.24M	1.97	875,927 shs	201,000 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-0.32%	+1.98%	+37.95%	+43.72%	+122.30%
IMA ImageneBio	-1.41%	-8.26%	-14.36%	-13.45%	-64.36%
KROS Keros Therapeutics	-1.07%	-1.07%	+8.39%	+7.86%	-29.51%
PEPG PepGen	0.00%	+3.58%	+64.77%	+125.53%	+167.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$3.18 +2.9%	$2.59	$1.21 ▼ $3.60	$223.46M	0.37	364,901 shs	315,369 shs
IMA ImageneBio	$4.85 -0.8%	$5.66	$3.94 ▼ $9.47	$55.45M	0.7	11,092 shs	15,462 shs
KROS Keros Therapeutics	$11.32 +1.9%	$10.81	$9.69 ▼ $22.55	$220.28M	1.01	192,149 shs	65,635 shs
PEPG PepGen	$3.11 -2.2%	$2.46	$1.30 ▼ $7.80	$220.24M	1.97	875,927 shs	201,000 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-0.32%	+1.98%	+37.95%	+43.72%	+122.30%
IMA ImageneBio	-1.41%	-8.26%	-14.36%	-13.45%	-64.36%
KROS Keros Therapeutics	-1.07%	-1.07%	+8.39%	+7.86%	-29.51%
PEPG PepGen	0.00%	+3.58%	+64.77%	+125.53%	+167.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$8.00	151.57% Upside
IMA ImageneBio	2.20	Hold	$29.00	497.94% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	81.10% Upside
PEPG PepGen	2.71	Moderate Buy	$11.50	269.77% Upside

Current Analyst Ratings Breakdown

Latest IMA, ABOS, KROS, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
IMA ImageneBio	$800K	68.81	N/A	N/A	$12.52 per share	0.39
KROS Keros Therapeutics	$244.06M	0.92	$4.62 per share	2.45	$13.23 per share	0.86
PEPG PepGen	N/A	N/A	N/A	N/A	$1.73 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.63	N/A	N/A	N/A	N/A	-136.27%	-81.64%	11/11/2026 (Estimated)
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)

Latest IMA, ABOS, KROS, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.21	2.47	2.47
IMA ImageneBio	N/A	21.47	21.47
KROS Keros Therapeutics	N/A	21.96	21.96
PEPG PepGen	N/A	13.36	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
IMA ImageneBio	75.00%
KROS Keros Therapeutics	71.56%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
IMA ImageneBio	2.22%
KROS Keros Therapeutics	12.60%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	72.32 million	64.94 million	Optionable
IMA ImageneBio	70	11.35 million	11.10 million	Not Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable
PEPG PepGen	30	69.26 million	68.36 million	Not Optionable

IMA, ABOS, KROS, and PEPG Headlines

Recent News About These Companies

ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG

August 26, 2026 | marketbeat.com

600,000 Shares in PepGen, Inc. $PEPG Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG

August 17, 2026 | marketbeat.com

PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 16, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings

August 11, 2026 | marketbeat.com

PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS

August 8, 2026 | marketbeat.com

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

August 7, 2026 | msn.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026 | businesswire.com

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026 | businesswire.com

PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance

July 14, 2026 | finance.yahoo.com

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

July 8, 2026 | stockhouse.com

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

10 Best NASDAQ Stocks Under $5 to Buy Right Now

May 18, 2026 | insidermonkey.com

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

May 18, 2026 | finance.yahoo.com

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

May 13, 2026 | zacks.com

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

May 7, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 30, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 28, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

April 26, 2026 | theglobeandmail.com

Stifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)

April 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, ABOS, KROS, and PEPG Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$3.18 +0.09 (+2.91%)

As of 04:00 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ImageneBio NASDAQ:IMA

$4.85 -0.04 (-0.82%)

As of 03:57 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Keros Therapeutics NASDAQ:KROS

$11.32 +0.21 (+1.89%)

As of 04:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

PepGen NASDAQ:PEPG

$3.11 -0.07 (-2.20%)

As of 04:00 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, ABOS, KROS, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, ABOS, KROS, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, ABOS, KROS, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, ABOS, KROS, and PEPG Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

ImageneBio NASDAQ:IMA

Keros Therapeutics NASDAQ:KROS

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, ABOS, KROS, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, ABOS, KROS, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, ABOS, KROS, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, ABOS, KROS, and PEPG Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

ImageneBio NASDAQ:IMA

Keros Therapeutics NASDAQ:KROS

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools